Mimedx Group Inc (MDXG) 7.34 $MDXG MiMedx Annou
Post# of 273258
Posted On: 09/03/2016 3:07:26 AM
Mimedx Group Inc (MDXG) 7.34 $MDXG
MiMedx Announces Nationwide Launch of AmnioFill(TM)
PR Newswire - Thu Sep 01, 3:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its plans for the nationwide launch of AmnioFill(TM), the first product in the MiMedx placental collagen matrix product family to be commercially launched.
MDXG: 7.34 (+0.20)
MiMedx Provides Update On Key Clinical Trials
PR Newswire - Tue Aug 30, 5:10PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided an update today on the status of key clinical trials.
MDXG: 7.34 (+0.20)
MiMedx To Attend The Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 11:21AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will attend the Morgan Stanley Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, September 14, 2016, at the Grand Hyatt New York.
MDXG: 7.34 (+0.20)
MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix(TM) Technology
PR Newswire - Mon Aug 29, 10:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to its intellectual property portfolio.
MDXG: 7.34 (+0.20)
MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
PR Newswire - Mon Aug 22, 10:08AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that in light of the media attention and in the wake of concerns related to the Zika virus, the Company is reiterating its long standing processing safety standards for the terminal sterilization of MiMedx amniotic allografts. The MiMedx flagship amniotic allografts have always been terminally sterilized, and the Company's proprietary PURION® Process has continually used terminal sterilization as an essential part of the process. In anticipation of questions related to the Zika virus, MiMedx is reconfirming the rigorous product safety methods and practices followed by the Company in the processing of its amniotic allografts as well as restating its precise standards for screening of placenta donors.
MDXG: 7.34 (+0.20)
MiMedx announces ruling from PTAB on its embossment patent
PR Newswire - Thu Aug 11, 1:51PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today a ruling has been rendered from the Patent Trial and Appeal Board ("PTAB"
of the United States Patent and Trademark Office with regard to MiMedx's United States Patent No. 8,597,687 related to the embossment of tissues. This embossment is a method for the clinician to determine which side is "up." This patent is not related to the EpiFix® or AmnioFix® patents, other than for the embossment.
MDXG: 7.34 (+0.20)
MiMedx to Present at the 36th Annual Canaccord|Genuity Growth Conference
PR Newswire - Wed Aug 03, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will present at the 36th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP & Chief Commercialization Officer, are scheduled to present on Thursday, August 11, 2016 at 11:30 a.m. eastern time, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.34 (+0.20)
How These Healthcare Stocks are Performing? -- Neovasc, MiMedx, InspireMD, and Amedica
PR Newswire - Wed Aug 03, 7:30AM CDT
The Medical Appliances and Equipment space remains a strong industry which is expected to continue growing given the high need and demand for health care and related instruments. Stock-Callers.com turns investors' attention to the following stocks in review: Neovasc Inc. (NASDAQ: NVCN), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (NYSEMKT: NSPR), and Amedica Corp. (NASDAQ: AMDA). Register now and get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
NSPR: 0.14 (unch), MDXG: 7.34 (+0.20), NVCN: 0.58 (+0.01), AMDA: 0.86 (-0.01)
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
PR Newswire - Tue Jun 21, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline" and Liventa Bioscience, Inc. ("Liventa" for false advertising claims asserted against each of them by MiMedx.
MDXG: 7.34 (+0.20)
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
PR Newswire - Wed Jun 01, 4:43PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed independent clinical case series of MiMedx EpiFix® allografts has been published. The paper, "Bone and Tendon Coverage via Dehydrated Human Amniotic/Chorionic Membrane and Split-Thickness Skin Grafting," was electronically published in the Journal of Reconstructive Microsurgery.
MDXG: 7.34 (+0.20)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company" (NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 5.25 (+0.11), MDXG: 7.34 (+0.20)
MiMedx To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu May 26, 1:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Wednesday, June 8th at 4:30 p.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.34 (+0.20)
MiMedx to Attend the 13th Annual Craig-Hallum Institutional Investor Conference
PR Newswire - Mon May 23, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will attend the 13th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, June 1, 2016, at The Depot Renaissance Minneapolis Hotel.
MDXG: 7.34 (+0.20)
MiMedx Provides Reminder of May 18th Annual Shareholders Meeting
PR Newswire - Tue May 17, 12:15PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided a reminder for the Company's Annual Shareholder meeting tomorrow, May 18, 2016, as well as a reminder that the annual meeting will be at the newer MiMedx facility located at 1828 West Oak Parkway, Marietta, Georgia. This facility is in the same business park as the MiMedx corporate headquarters and is located near the middle of the business park approximately one-half mile from the Company's main office.
MDXG: 7.34 (+0.20)
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.25 (+0.11), MDXG: 7.34 (+0.20)
MiMedx to Present at the UBS 2016 Global Healthcare Conference
PR Newswire - Mon May 16, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the UBS 2016 Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Tuesday, May 24, 2016 at 10:30 a.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.34 (+0.20)
MiMedx Comments on Flawed Osiris Data Review
PR Newswire - Tue May 03, 8:04AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws in a recent data review reported by Osiris Therapeutics, Inc.
MDXG: 7.34 (+0.20)
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference
PR Newswire - Thu Apr 28, 10:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will participate in the 41st Annual Deutsche Bank Securities Healthcare Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate on Thursday, May 5, 2016 at 10:00 a.m. eastern time, at the InterContinental Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
DB: 14.90 (+0.21), MDXG: 7.34 (+0.20)
MiMedx Announces First Quarter 2016 Results
PR Newswire - Mon Apr 25, 7:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its results for the first quarter of 2016.
MDXG: 7.34 (+0.20)
MiMedx Announces Release Date for 2016 First Quarter Results
PR Newswire - Tue Apr 19, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that its results for the first quarter ended March 31, 2016, will be released before the opening of the market on Tuesday, April 26, 2016. MiMedx will host a live broadcast of its first quarter conference call on Tuesday, April 26, 2016, at 10:30 a.m. Eastern Time. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 7.34 (+0.20)
MiMedx Announces Nationwide Launch of AmnioFill(TM)
PR Newswire - Thu Sep 01, 3:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its plans for the nationwide launch of AmnioFill(TM), the first product in the MiMedx placental collagen matrix product family to be commercially launched.
MDXG: 7.34 (+0.20)
MiMedx Provides Update On Key Clinical Trials
PR Newswire - Tue Aug 30, 5:10PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided an update today on the status of key clinical trials.
MDXG: 7.34 (+0.20)
MiMedx To Attend The Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 11:21AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will attend the Morgan Stanley Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, September 14, 2016, at the Grand Hyatt New York.
MDXG: 7.34 (+0.20)
MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix(TM) Technology
PR Newswire - Mon Aug 29, 10:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today an update to its intellectual property portfolio.
MDXG: 7.34 (+0.20)
MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
PR Newswire - Mon Aug 22, 10:08AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that in light of the media attention and in the wake of concerns related to the Zika virus, the Company is reiterating its long standing processing safety standards for the terminal sterilization of MiMedx amniotic allografts. The MiMedx flagship amniotic allografts have always been terminally sterilized, and the Company's proprietary PURION® Process has continually used terminal sterilization as an essential part of the process. In anticipation of questions related to the Zika virus, MiMedx is reconfirming the rigorous product safety methods and practices followed by the Company in the processing of its amniotic allografts as well as restating its precise standards for screening of placenta donors.
MDXG: 7.34 (+0.20)
MiMedx announces ruling from PTAB on its embossment patent
PR Newswire - Thu Aug 11, 1:51PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today a ruling has been rendered from the Patent Trial and Appeal Board ("PTAB"
of the United States Patent and Trademark Office with regard to MiMedx's United States Patent No. 8,597,687 related to the embossment of tissues. This embossment is a method for the clinician to determine which side is "up." This patent is not related to the EpiFix® or AmnioFix® patents, other than for the embossment. MDXG: 7.34 (+0.20)
MiMedx to Present at the 36th Annual Canaccord|Genuity Growth Conference
PR Newswire - Wed Aug 03, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will present at the 36th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP & Chief Commercialization Officer, are scheduled to present on Thursday, August 11, 2016 at 11:30 a.m. eastern time, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.34 (+0.20)
How These Healthcare Stocks are Performing? -- Neovasc, MiMedx, InspireMD, and Amedica
PR Newswire - Wed Aug 03, 7:30AM CDT
The Medical Appliances and Equipment space remains a strong industry which is expected to continue growing given the high need and demand for health care and related instruments. Stock-Callers.com turns investors' attention to the following stocks in review: Neovasc Inc. (NASDAQ: NVCN), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (NYSEMKT: NSPR), and Amedica Corp. (NASDAQ: AMDA). Register now and get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
NSPR: 0.14 (unch), MDXG: 7.34 (+0.20), NVCN: 0.58 (+0.01), AMDA: 0.86 (-0.01)
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
PR Newswire - Tue Jun 21, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline"
and Liventa Bioscience, Inc. ("Liventa" for false advertising claims asserted against each of them by MiMedx. MDXG: 7.34 (+0.20)
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
PR Newswire - Wed Jun 01, 4:43PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed independent clinical case series of MiMedx EpiFix® allografts has been published. The paper, "Bone and Tendon Coverage via Dehydrated Human Amniotic/Chorionic Membrane and Split-Thickness Skin Grafting," was electronically published in the Journal of Reconstructive Microsurgery.
MDXG: 7.34 (+0.20)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"
(NASDAQ: OSIR) concerning possible violations of federal securities laws. OSIR: 5.25 (+0.11), MDXG: 7.34 (+0.20)
MiMedx To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu May 26, 1:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Wednesday, June 8th at 4:30 p.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.34 (+0.20)
MiMedx to Attend the 13th Annual Craig-Hallum Institutional Investor Conference
PR Newswire - Mon May 23, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will attend the 13th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, June 1, 2016, at The Depot Renaissance Minneapolis Hotel.
MDXG: 7.34 (+0.20)
MiMedx Provides Reminder of May 18th Annual Shareholders Meeting
PR Newswire - Tue May 17, 12:15PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided a reminder for the Company's Annual Shareholder meeting tomorrow, May 18, 2016, as well as a reminder that the annual meeting will be at the newer MiMedx facility located at 1828 West Oak Parkway, Marietta, Georgia. This facility is in the same business park as the MiMedx corporate headquarters and is located near the middle of the business park approximately one-half mile from the Company's main office.
MDXG: 7.34 (+0.20)
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.25 (+0.11), MDXG: 7.34 (+0.20)
MiMedx to Present at the UBS 2016 Global Healthcare Conference
PR Newswire - Mon May 16, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the UBS 2016 Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Tuesday, May 24, 2016 at 10:30 a.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.34 (+0.20)
MiMedx Comments on Flawed Osiris Data Review
PR Newswire - Tue May 03, 8:04AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws in a recent data review reported by Osiris Therapeutics, Inc.
MDXG: 7.34 (+0.20)
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference
PR Newswire - Thu Apr 28, 10:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will participate in the 41st Annual Deutsche Bank Securities Healthcare Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate on Thursday, May 5, 2016 at 10:00 a.m. eastern time, at the InterContinental Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
DB: 14.90 (+0.21), MDXG: 7.34 (+0.20)
MiMedx Announces First Quarter 2016 Results
PR Newswire - Mon Apr 25, 7:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its results for the first quarter of 2016.
MDXG: 7.34 (+0.20)
MiMedx Announces Release Date for 2016 First Quarter Results
PR Newswire - Tue Apr 19, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that its results for the first quarter ended March 31, 2016, will be released before the opening of the market on Tuesday, April 26, 2016. MiMedx will host a live broadcast of its first quarter conference call on Tuesday, April 26, 2016, at 10:30 a.m. Eastern Time. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 7.34 (+0.20)
(0)
(0)Scroll down for more posts ▼